Youre basically hammering GLP1 and GIP with those 2 which at best is useless, and at worse dimishes efficacy of either
Highlights: Retatrutide targets GLP-1, GIP, and glucagon to reduce appetite, regulate fat storage, and manage blood sugar A trial showed a higher dose of Retatrutide produced 20% more weight loss over 48 weeks Common side effects include diarrhea, nausea, and vomiting , with at least one death reported Trusted Source Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial Go to source)
Retatrutide extends this research framework by adding glucagon receptor activity to a GIP and GLP-1 receptor signaling profile
Lower doses remain effective for those who cannot tolerate maximum dosing
Were a few years in, but it usually takes about 20 years of patient data to fully understand the true risk of a drug
The protocol is simple but requires attention to several details that affect absorption and comfort